Wellington Strategic European Equity Fund USD S Accumulating Unhedged

RISK AND REWARD PROFILE

1 2 3 4 5 6 7
Lowest Risk Highest Risk

Capital at risk: please refer to the bottom of this page for details about the Risk & Reward Profile.

MORNINGSTAR™ RATING*: ★★★

FUND DETAILS*

Fund Inception: December 2011 Share Class Inception: March 2014 Fund Assets: EUR 1.5 billion NAV: USD 17.24

*This fund is no longer accepting new investors and may have restrictions on additional investment. Please contact your Wellington relationship manager prior to making additional subscriptions.

KEY INFORMATION

Domicile: Ireland

Regulatory Regime: UCITS

Legal Structure: Public Limited Company

Dealing Frequency: Daily

Country Registration: Chile, France, Germany, Ireland, Italy, Norway, Singapore*, Spain, Sweden, Switzerland, United Kingdom.

ISIN: IEOOB9FQ4253 Bloomberg: WSEENUH ID Sedol: B9FQ425 Lipper: 68207191 WKN: A1W03R

*Restricted scheme

FUND CHARACTERISTICS

Asset-Weighted Market
Capitalisation:
Beta (3 Yr):
1.00
Tracking Risk (3 Yr, Annualised):
3.8%
Turnover:
55.1%

FEES AND PRICING

Minimum Investment: USD 1 million Management Fee: 0.70% Ongoing Charges Figure *: 0.79%

"The Ongoing Charges Figure represents all annual expenses and additional charges taken from the fund. A more detailed description of the charges that apply to the Fund is set out in the section "Charges of the Umbrella Fund" in the Prospectus. The ongoing charges figure may change over time.

For more information, please visit www.wellingtonfunds.com

SUMMARY OF INVESTMENT OBJECTIVE


The Wellington Strategic European Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of predominantly European-domiciled companies that are believed to benefit from earnings and cash flow growth that are greater than the market average. Although the Fund is not constructed relative to a benchmark, the MSCI Europe index will serve as a reference benchmark.

FUND PERFORMANCE (%)

TOTAL RETURNS NET OF FEES AND EXPENSES

	YTD	1 MO	3 MOS	1 YR	3 YRS	5 YRS	10 YRS	SINCE INCEPTION
USD S Acc	11.1	-1.1	8.2	34.1	10.4	11.8	-	7.7
MSCI Europe Net	11.8	-1.4	7.4	35.1	8.7	10.3	-	4.6

CALENDAR YEAR RETURNS



DISCRETE ANNUAL PERFORMANCE

	JUL '20 - JUN '21	JUL '19 - JUN '20	JUL '18 - JUN '19	JUL '17 - JUN '18	JUL '16 - JUN '17
USD S Acc	34.1	-0.8	1.1	5.0	23.7
MSCL Furone Net	35.1	-6.8	19	53	21.1

Past results are not necessarily indicative of future results and an investment can lose value.

The inception date of the USD S Acc share class is 7 March 2014. | Fund returns shown are net of USD S Acc share class fees and expenses. Fund returns shown are net of actual (but not necessarily maximum) withholding and capital gains tax but are not otherwise adjusted for the effects of taxation and assume reinvestment of dividends and capital gains. The index returns, where applicable, are shown net of maximum withholding tax and assume reinvestment of dividends. Periods greater than one year are annualised. If an investor's own currency is different from the currency in which the fund is denominated, the investment return may increase or decrease as a result of currency fluctuations. | Please note the fund has a swing pricing mechanism in place. | If the last business day of the month is not a business day for the Fund, performance is calculated using the last available NAV. This may result in a performance differential between the fund and the index. | Source: Fund - Wellington Management. Index - MSCI.

FUND MANAGEMENT



WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

CONCENTRATION: Concentration of investments within securities, sectors or industries, or geographical regions may impact performance.

CURRENCY: The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.

EMERGING MARKETS: Emerging markets may be subject to custodial and political risks, and volatility. Investment in foreign currency entails exchange risks.

EQUITIES: Investments may be volatile and may fluctuate according to market conditions, the performance of individual companies and that of the broader equity market.

HEDGING: Any hedging strategy using derivatives may not achieve a perfect hedge.

MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.

SMALL AND MID-CAP COMPANY: Small and mid-cap companies' valuations may be more volatile than those of large cap companies. They may also be less liquid.


SUSTAINABILITY RISK: A Sustainability Risk can be defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of an investment

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and pre-investment disclosures. For the latest NAV, please visit www.fundinfo.com.

COUNTRY DISTRIBUTION

% OF EQUITY 33.4 United Kingdom 18 1 Germany 14.6 France 10.3 Sweden Switzerland Belgium Netherlands 2.6 Portugal 1.8 11.9 9 27

SECTOR DISTRIBUTION



Totals may not add up to 100% due to rounding.

Benchmark

Totals may not add up to 100% due to rounding.

TOP 10 HOLDINGS

Fund

COMPANY NAME COUNTRY INDUSTRY		INDUSTRY	% OF EQUITY	
Novartis AG	Switzerland	Pharma, Biotech & Life Sciences	4.5	
GlaxoSmithKline Plc	United Kingdom	Pharma, Biotech & Life Sciences	4.5	
UCB SA	Belgium	Pharma, Biotech & Life Sciences	4.2	
AstraZeneca PLC	United Kingdom	Pharma, Biotech & Life Sciences	4.0	
UBS Group AG	Switzerland	Diversified Financials	3.7	
Fresenius SE & Co	Germany	Health Care Equipment & Services	3.2	
United Internet AG	Germany	Telecommunication Services	3.0	
Alfa Laval AB	Sweden	Capital goods	3.0	
Qiagen NV	Germany	Pharma, Biotech & Life Sciences	2.6	
Assa Abloy AB	Sweden	Capital goods	2.6	
Total of Top 10			35.3	
Number of Equity Names			60	

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund will hold any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.